Biotech Values

[DewDiligence]

so hospitals will switch if studies are successful

Regardless of the pricing, I think sodrock’s original point in this thread is well-taken—i.e. the new oral anticoagulants will not be an easy sell in the hospital setting because they are so radically different from the SoC. I’ll be surprised if as much as 10% of the aggregate sales of all of the new oral anticoagulants comes from the hospital setting.